Esperion Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGEsperion Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 80), indicating clear outperformance against the broad market. Earnings growth of 52% provides fundamental context to the price action. Investors should exercise caution due to high volatility (92% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.15 | +0.71% | ABOVE |
| 50 SMA | $2.88 | +10.13% | ABOVE |
| 100 SMA | $2.88 | +9.97% | ABOVE |
| 150 SMA | $3.12 | +1.59% | ABOVE |
| 200 SMA | $3.03 | +4.47% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ESPR in an uptrend right now?
ESPR has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is ESPR overbought or oversold?
ESPR's RSI (14) is 65. The stock is in neutral territory, neither overbought nor oversold.
Is ESPR outperforming the market?
ESPR has a Relative Strength (RS) Rating of 80 out of 99. Yes, ESPR is a market leader, outperforming 80% of all stocks over the past 12 months.
Where is ESPR in its 52-week range?
ESPR is trading at $3.17, which is 76% of its 52-week high ($4.18) and 69% above its 52-week low ($0.95).
How volatile is ESPR?
ESPR has a Beta of 1.92 and 52-week volatility of 92%. It's more volatile than the S&P 500 - expect bigger swings.